No Data
No Data
Henan Lingrui Pharmaceutical's (SHSE:600285) Five-year Earnings Growth Trails the 29% YoY Shareholder Returns
Henan Lingrui Pharmaceutical Plans Further 50-Million-Yuan Investment in Xiamen Jinyixing Fund; Shares Up 5%
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
Henan Lingrui Pharmaceutical (600285.SH): Intends to invest an additional 50 million yuan to subscribe for more shares of Jinbaoxuan.
On September 13, Lingrui Pharmaceutical (600285.SH) announced that since its establishment, Jin Yixing has maintained a good development trend. In order to fully leverage the strengths of all parties and further expand the company's investment channels, the company plans to use its own funds of 50 million yuan to add subscriptions to Jin Yixing as a limited partner, optimizing the company's investment and business layout in technology innovation and domestic demand markets according to its strategic planning. After the additional investment, the company's cumulative subscribed amount in Jin Yixing reaches 150 million yuan, accounting for 16.6667% of the total subscribed capital of Jin Yixing.
Henan Lingrui Pharmaceutical Semi-Annual Report 2024
Summary of Henan Lingrui Pharmaceutical's Half-Year Report in 2024.
No Data
No Data